Maintenance of Anaesthesia With Sevoflurane Versus Propofol and the Occurrence of Postoperative Headache.
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03789370 |
|
Recruitment Status : Unknown
Verified November 2019 by Chrysanthi Batistaki, Attikon Hospital.
Recruitment status was: Recruiting
First Posted : December 28, 2018
Last Update Posted : November 19, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Headache | Drug: Propofol Drug: Sevoflurane | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 130 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Participant, Outcomes Assessor) |
| Masking Description: | The patient and the outcomes assessor will not know what kind of anaesthetic drug was used for maintainance of anaesthesia. |
| Primary Purpose: | Prevention |
| Official Title: | Maintenance of Anaesthesia With Sevoflurane Versus Propofol and the Occurrence of Postoperative Headache. |
| Actual Study Start Date : | November 7, 2014 |
| Estimated Primary Completion Date : | October 30, 2020 |
| Estimated Study Completion Date : | October 30, 2020 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Propofol
Total intravenous anaesthesia with propofol for maintainance of anaesthesia.Dose adjusted according to the Bispectral Index (BIS) indication (maintained 40-50). Initial dose 10 mg/kg/h for10 min, 8 mg/kg/h for 10 min and then 6 mg/kg/h).
|
Drug: Propofol
Maintanance of general anaesthesia with propofol |
|
Active Comparator: Sevoflurane
Sevoflurane for maintainance of anaesthesia. Dose 1 MAC adjusted according to the Bispectral Index (BIS) indication (maintained 40-50).
|
Drug: Sevoflurane
Maintainance of general anaesthesia with sevoflurane. |
- incidence of postoperative headache (yes or no) [ Time Frame: up to 24 hours postoperatively ]Rate of postoperative headache in patients receiving sevoflurane versus propofol (yes or no headache)
- Nausea and vomiting [ Time Frame: up to 24 hours postoperatively ]Which anaesthetic (propofol or sevoflurane) is associated with less postoperative nausea and vomiting
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- ASA I-III
- scheduled operation under general anaesthesia
- operations <4 hours
- minorgynaecological operatios (leiomyomectomy)
- hernia repair
- arthroscopic procedurs
- minor orthopaedic operations without the use of tourniquet or cement
- saphenectomy
- minor urologic operations
- minor other operations of general surgery
Exclusion Criteria:
- age <18 and >65 years old
- ASA>III
- Diseases of the central nervous system (ie Parkinsons's disease, Multiple sclerosis, previous ischaemic attack, hydrocephalus, seizure disorder, etc)
- Psychosis under medication
- Cognitive impairement or/and inability to fill in the questionaires
- Allergy or contraindication to the study protocol included drugs
- Operations of more than 4 hours duration
- Head and neck procedures, procedures with neck extension (eg thyroidectomy), ENT procedures
- renal impairement
- hepatic impairement
- patient refusal
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03789370
| Contact: Chrysanthi Batistaki, MD, PhD | 00302105832371 | chrysabatistaki@yahoo.gr | |
| Contact: Georgia Kostopanagiotou, MD, PhD | 00302105832371 | banesthclin@attikonhospital.gr |
| Greece | |
| 2nd Department of Anesthesiology, Attikon Hospital, 1 Rimini str. | Recruiting |
| Athens, Greece, 12462 | |
| Contact: Chrysanthi Batistaki, MD, PhD 0030 210 5832371 chrysabatistaki@yahoo.gr | |
| Responsible Party: | Chrysanthi Batistaki, Assistant Professor of Anaesthesiology, Attikon Hospital |
| ClinicalTrials.gov Identifier: | NCT03789370 |
| Other Study ID Numbers: |
06-11-14 |
| First Posted: | December 28, 2018 Key Record Dates |
| Last Update Posted: | November 19, 2019 |
| Last Verified: | November 2019 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Headache Pain Neurologic Manifestations Propofol Sevoflurane Hypnotics and Sedatives Central Nervous System Depressants |
Physiological Effects of Drugs Anesthetics, Intravenous Anesthetics, General Anesthetics Platelet Aggregation Inhibitors Anesthetics, Inhalation |

